Thanks J for cleaning the board up. I'm thankful this
Thanks J for cleaning the board up.
I'm thankful this forum is available as a resource for fair and honest discussion of investing and trading opportunities. The major difference I hope to see continue is reasonable and real discussion of opportunities from smart fundamental and technical traders. IHUB simply allows to many charlatans to "take the mike" without any real control over b.s..
That being said, if anyone has legitimate concerns about any stock, then some chatter and discourse involving links and boots on the ground experienced discussion are very welcome in my book. I know how to spot red flags in penny land. I know how to make money on pump n dumps. To me, making money in the market is no different when playing pennies or big boards, with obvious exceptions such as dividend plays.
EWSI IMO is one of those rare risk/reward penny plays that can offer huge gains in the not to distant future. At this point with their filed results I would have expected the market to provide a much higher valuation. But, it hasn't...yet. My bet is that it will...and soon. The charts say up. Once we crack 10 on hvy volume it will be for very clear fundamental growth reasons. This is where the idea of an actual investment in an OTC stock starts to make sense. We'll know we made the right decision if and when we get there. Again, IMO it shouldn't be very long until we realize a fundamental revaluation of the stock based on growth and rapidly increasing revenue streams. On the flip side, anyone that plays OTC stocks should realize that 99 percent of these stocks should be viewed as short term swing plays. That's just the nature of the OTC world. QB/QX companies offer fully audited and SEC compliance for further DD than pink listed companies, which are very very risky for anything other than day/very short swings.
EWSI - Dilution will continue until the company can prove its cash flow model and support growth and operational expenses with free cash flow. IMO this is at the root of the risk/reward play for those actually considering an investment here. If EWSI can get the necessary capital to fuel growth without sacrificing their capital structure to much, then those of us early to the opportunity will make out extremely well.
Everyone has their own metrics to decide their personal risk profile. For me personally I'm comfortable with EWSI having an O/S of 360Mish FY2014 as long as the balance sheet is clearly pointing the way to a successful net positive cash flow model. I will re-evaluate EWSI after the first half of 2014 is filed with the SEC. Everyone has to make their own decisions with their own money with trading tools that they're comfortable using. Again, 99 percent of all OTC are for flipping only. We are absolutely taking a road less traveled by accumulating and holding an OTC company as their business model develops. Most of the time this approach will fail with OTC. There are simply to many crooks leading OTC companies that are only out to line their own pockets. I have obviously taken an exception with EWSI.
Can EWSI fail? Of course it can. Businesses fail every day. I weigh the market opportunity (150B), the players that are already present in the industry (opportunity for another leader??), and the business model/leadership's ability to execute and gain market share and produce a repeatable and growing revenue stream that supports operations/continued growth/and a healthy balance sheet that can be analyzed fundamentally. If EWSI is really going to up list (I believe they are), then a fundamentally healthy business model that clearly shows an industry/company that can provide repeatable profit margins is necessary. I think they can.
I think gross margins will stay in the 25 - 30 percent zone.
Rapid rev growth will continue Qtr over Qtr (IMO this constitutes 30 percent or greater) for at least two more years.
Operating costs must stabilize and allow for organic growth to move the company toward cash flow positive. Expenses and smart use of the capital structure are a must.
I love the process of securing assets for debt relief and some modest capital outlays that allows for an ROI of one year or less for EWSI. They've proven it with SURF. 2TRG is next. There may in fact be several more this year. This will add shareholder equity quickly and should help EWSI to be recognized as a small cap fundamental growth play more than anything else.
Anyway, just some thoughts on a lazy Sunday morning. Some things to consider as we head into Q1 2014.
I do hope everyone makes a million here.
E-Waste Systems, Inc. (EWSI) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Changshan Grabs Attention This National Day You know, I blinked twice when I saw Changshan's tourist numbers this year. During the 2026 National Day holiday, they managed to snag 503,000 visitors. That's up by a whopping 22.8% from last year. If that doesn't grab your attention, I don't know what will. We're talking record numbers here, folks, and that's the kind of...
Continue Reading
Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....
Continue Reading
Revving Up Wearables with Next-Gen Graphics Well, folks, VeriSilicon's at it again, rolling out some cutting-edge technology in the form of their spanking new GCNanoOptimaV GPU IP. If you're scratching your head wondering what this means for your wrist-bound gadgets, hang tight—I'm about to spell it out. Architectural Innovations: Striking the Balance Here's the scoop...
Continue Reading
A Strategic Addition to Jungbunzlauer’s Board In what feels like a significant move, Jungbunzlauer has roped in Johan Westman to join its Board of Directors. The man’s got pedigree—a CEO at AAK AB, a Swedish powerhouse dealing in plant-based oils, he's taking a seat at Jungbunzlauer’s table. So, what does this mean for Jungbunzlauer? Well, the potential for...
Continue Reading
Revolutionizing AI-Powered Global Sourcing Here's the scoop from Taipei: Taiwantrade's just dropped ASTRA, their brand-spanking-new AI sourcing assistant, and it's got the industry buzzing. When it comes to cutting through the clutter and finding the right supplier, this could change the game for how international buyers scrape deals out of Taiwan. Simplifying Complex...
Continue Reading
Shenzhen: The Heartbeat of Future Business Shenzhen isn't just a city on the map. It's an exploding innovation powerhouse, a place where global business leaders will rub shoulders this November for the 2026 APEC CEO Summit. This ain't your average conference, my friends. CCPIT (China's national trade pushers) are hosting it from November 17 to 18, promising a powerhouse...
Continue Reading
Boosting Brain Horizons: The Need for Donations Urgency clings to the air like smoke around a campfire when it comes to funding brain research. The American Academy of Neurology (AAN) knows this, and they've kicked off their year-end giving campaign, trying to rope in every penny they can muster for the AAN Research Program. With brain diseases lining up like unwanted...
Continue Reading
Battle Against the Holiday Cyber Threats This ain't just about slipping on an ugly sweater this holiday season. The ugly truth is as the colder weather rolls around, so do the cyber vultures—praying on the unsuspecting, especially our seniors. Fraudsters are cranking up the heat, exploiting online shopping sprees, hefty travel plans, and even the warm embrace of a...
Continue Reading
KT&G Climbs to New Heights with Record-Setting Q3 If you're eyeballing the markets like a hawk, KT&G (KRX: 033780) just gave you something to squawk about. In the world of stocks, milestones are few and far between, but KT&G is handing out milestones like candy in Q3. They rolled out their numbers for the quarter, and let me tell ya, this was no pie-in-the-sky nonsense....
Continue Reading
Enter Mercury Alerts in a Changing Trading Landscape Damn, if there ain't some days that throw us a curveball, today's one of them. Since Cboe pulled the plug on the beloved Trade Alert, it's like chopping off a trader's lifeline without a backup. Just when everyone was getting cozy with the way Trade Alert fed the options flow into our screens, here comes Harmeet Goindi...
Continue Reading
Top 5 Most Recently Viewed Articles
Join the Upcoming Class Action Against Walgreens for WBA Shareholders The Gross Law Firm has issued an important notice for shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) regarding a potential class action lawsuit. If you purchased shares of WBA within the specified dates, you may want to consider your options for participation. Class Action Overview This...
Continue Reading
US Employment Surge Sparks Optimism in Asian Markets By Jamie McGeever As Asian markets prepare to open, the global economic landscape is shifting dramatically, spurred by astonishing U.S. employment figures. This unexpected data has shifted market perceptions and prompted investors to reconsider their strategies. Strong September Non-Farm Payrolls Report The report on...
Continue Reading
Understanding Your Rights as a Block, Inc. Investor For investors of Block, Inc. looking to recover their losses, it's crucial to understand the legal avenues available to them. The recent issues surrounding Block should encourage affected investors to seek assistance promptly. How to Recover Losses The Portnoy Law Firm is available to help investors navigate the...
Continue Reading
Highlights from Implantica AG's Annual General Meeting On a recent date, the annual general meeting (AGM) of Implantica AG (publ) took place in Ruggell. This important gathering allowed shareholders to review key proposals and resolutions put forth by the board of directors, all of which were adopted. Below is a detailed overview of the notable decisions made during this...
Continue Reading
Key Findings from BRIUMVI's 5-Year Trials TG Therapeutics, Inc. (NASDAQ:TGTX) has revealed impressive results from its long-term Phase 3 trials, ULTIMATE I & II, which focus on BRIUMVI (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis (RMS). These findings were presented at the respected European Committee for Treatment and Research in Multiple...
Continue Reading